For autoimmune bullous diseases (AIBD) such as bullous pemphigoid (BP) and pemphigus an increased risk of COVID-19 infection and mortality was reported, with oral prednisolone (dose ≥10 mg/day) and treatment of rituximab being a risk factor. A population-based cohort study showed an increased COVID-19 associated mortality in patients with BP, but not in patients with pemphigus vulgaris. Here, we provide the findings of an international registry for health care providers about COVID-19 infection in patients with AIBD, reporting on timing and clinical presentation of COVID-19 infection, AIBD disease activity and outcome.

Impact of COVID-19 in patients with autoimmune bullous diseases: Report from an international registry / Joost M. Meijer, Hanan Rashid, Styliani Vergadi, Emiliano Antiga, Pamela Vezzoli, Riccardo Balestri, Aikaterini Patsatsi, Soner Uzun, Dusan Skiljevic, Hana Jedlickova, Lucia Janickova, Alberto Corrà, Alessandra Ponziani, Claudia Günther, Giuseppe Cianchini, Matthias Schefzyk, Angelo Marzano, Giovanni Di Zenzo, Iakov Shimanovich, Janet Fairley, Jose M. Mascaró Jr, Marzia Caproni, Roberto Maglie, Enno Schmidt, Barbara Horváth. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 1468-3083. - ELETTRONICO. - (2023), pp. e1189-e1191. [10.1111/jdv.19242]

Impact of COVID-19 in patients with autoimmune bullous diseases: Report from an international registry

Emiliano Antiga;Marzia Caproni;Roberto Maglie;
2023

Abstract

For autoimmune bullous diseases (AIBD) such as bullous pemphigoid (BP) and pemphigus an increased risk of COVID-19 infection and mortality was reported, with oral prednisolone (dose ≥10 mg/day) and treatment of rituximab being a risk factor. A population-based cohort study showed an increased COVID-19 associated mortality in patients with BP, but not in patients with pemphigus vulgaris. Here, we provide the findings of an international registry for health care providers about COVID-19 infection in patients with AIBD, reporting on timing and clinical presentation of COVID-19 infection, AIBD disease activity and outcome.
2023
e1189
e1191
Joost M. Meijer, Hanan Rashid, Styliani Vergadi, Emiliano Antiga, Pamela Vezzoli, Riccardo Balestri, Aikaterini Patsatsi, Soner Uzun, Dusan Skiljevic, Hana Jedlickova, Lucia Janickova, Alberto Corrà, Alessandra Ponziani, Claudia Günther, Giuseppe Cianchini, Matthias Schefzyk, Angelo Marzano, Giovanni Di Zenzo, Iakov Shimanovich, Janet Fairley, Jose M. Mascaró Jr, Marzia Caproni, Roberto Maglie, Enno Schmidt, Barbara Horváth
File in questo prodotto:
File Dimensione Formato  
Acad Dermatol Venereol - 2023 - Meijer - Impact of COVIDâ 19 in patients with autoimmune bullous diseases Report from an.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 599.26 kB
Formato Adobe PDF
599.26 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1339091
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact